Table S1 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Phosphoproteins

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Xiaoqing Cheng (16918496) (author)
Άλλοι συγγραφείς:	Yirui Sun (16918499) (author), Maureen Highkin (16918502) (author), Nagalaxmi Vemalapally (16918505) (author), Xiaohua Jin (16918508) (author), Brandon Zhou (16918511) (author), Julie L. Prior (16918514) (author), Ashley R. Tipton (16918517) (author), Shunqiang Li (15123195) (author), Anton Iliuk (16918520) (author), Samuel Achilefu (11605234) (author), Ian S. Hagemann (15026769) (author), John R. Edwards (16918523) (author), Ron Bose (15045749) (author)
Έκδοση:	2025
Θέματα:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Antireceptors Breast Cancer Cell Cycle CDKs and CDK inhibitors Preclinical Models Organoids
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

_version_	1849927637588246528
author	Xiaoqing Cheng (16918496)
author2	Yirui Sun (16918499) Maureen Highkin (16918502) Nagalaxmi Vemalapally (16918505) Xiaohua Jin (16918508) Brandon Zhou (16918511) Julie L. Prior (16918514) Ashley R. Tipton (16918517) Shunqiang Li (15123195) Anton Iliuk (16918520) Samuel Achilefu (11605234) Ian S. Hagemann (15026769) John R. Edwards (16918523) Ron Bose (15045749)
author2_role	author author author author author author author author author author author author author
author_facet	Xiaoqing Cheng (16918496) Yirui Sun (16918499) Maureen Highkin (16918502) Nagalaxmi Vemalapally (16918505) Xiaohua Jin (16918508) Brandon Zhou (16918511) Julie L. Prior (16918514) Ashley R. Tipton (16918517) Shunqiang Li (15123195) Anton Iliuk (16918520) Samuel Achilefu (11605234) Ian S. Hagemann (15026769) John R. Edwards (16918523) Ron Bose (15045749)
author_role	author
dc.creator.none.fl_str_mv	Xiaoqing Cheng (16918496) Yirui Sun (16918499) Maureen Highkin (16918502) Nagalaxmi Vemalapally (16918505) Xiaohua Jin (16918508) Brandon Zhou (16918511) Julie L. Prior (16918514) Ashley R. Tipton (16918517) Shunqiang Li (15123195) Anton Iliuk (16918520) Samuel Achilefu (11605234) Ian S. Hagemann (15026769) John R. Edwards (16918523) Ron Bose (15045749)
dc.date.none.fl_str_mv	2025-11-24T23:25:03Z
dc.identifier.none.fl_str_mv	10.1158/0008-5472.30701383
dc.relation.none.fl_str_mv	https://figshare.com/articles/dataset/Table_S1_from_Breast_Cancer_Mutations_i_HER2_sup_V777L_sup_i_and_i_PIK3CA_sup_H1047R_sup_i_Activate_the_p21_CDK4_6_Cyclin_D1_Axis_to_Drive_Tumorigenesis_and_Drug_Resistance/30701383
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Antireceptors Breast Cancer Cell Cycle CDKs and CDK inhibitors Preclinical Models Organoids
dc.title.none.fl_str_mv	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
dc.type.none.fl_str_mv	Dataset info:eu-repo/semantics/publishedVersion dataset
description	<p>Phosphoproteins</p>
eu_rights_str_mv	openAccess
id	Manara_022f103c37cb595cab0827777118770c
identifier_str_mv	10.1158/0008-5472.30701383
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30701383
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug ResistanceXiaoqing Cheng (16918496)Yirui Sun (16918499)Maureen Highkin (16918502)Nagalaxmi Vemalapally (16918505)Xiaohua Jin (16918508)Brandon Zhou (16918511)Julie L. Prior (16918514)Ashley R. Tipton (16918517)Shunqiang Li (15123195)Anton Iliuk (16918520)Samuel Achilefu (11605234)Ian S. Hagemann (15026769)John R. Edwards (16918523)Ron Bose (15045749)CancerMolecular and Cellular BiologyTherapeutic Research and DevelopmentMethods and TechnologyBiological Agents & TherapiesAntibody-drug conjugatesAntireceptorsBreast CancerCell CycleCDKs and CDK inhibitorsPreclinical ModelsOrganoids<p>Phosphoproteins</p>2025-11-24T23:25:03ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/0008-5472.30701383https://figshare.com/articles/dataset/Table_S1_from_Breast_Cancer_Mutations_i_HER2_sup_V777L_sup_i_and_i_PIK3CA_sup_H1047R_sup_i_Activate_the_p21_CDK4_6_Cyclin_D1_Axis_to_Drive_Tumorigenesis_and_Drug_Resistance/30701383CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307013832025-11-24T23:25:03Z
spellingShingle	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance Xiaoqing Cheng (16918496) Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Antireceptors Breast Cancer Cell Cycle CDKs and CDK inhibitors Preclinical Models Organoids
status_str	publishedVersion
title	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
title_full	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
title_fullStr	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
title_full_unstemmed	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
title_short	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
title_sort	Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
topic	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Antireceptors Breast Cancer Cell Cycle CDKs and CDK inhibitors Preclinical Models Organoids

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Παρόμοια τεκμήρια